Voreloxin (SNS-595) HCl

Alias: Vosaroxin; SNS 595; SPC595; AG7352; SNS595; SPC-595; AG-7352; SNS-595; SPC 595; AG 7352; VVosaroxin

Cat No.:V1396 Purity: ≥98%

COA Product Data Instructions for use SDS

Voreloxin (SNS-595) HCl Chemical Structure CAS No.: 175519-16-1
Product category: Topoisomerase

This product is for research use only, not for human use. We do not sell to patients.

Size	Price	Stock	Qty
5mg
10mg
25mg
50mg
100mg
250mg
Other Sizes

ADD TO CART CHECKOUT BULK INQUIRY

1-708-310-1919 sales@invivochem.com

Other Forms of Voreloxin (SNS-595) HCl:

Voreloxin (SNS-595)

Official Supplier of:

Top Publications Citing lnvivochem Products

Nature 2021, 597(7874):119-125.

Cell 2020,183:1202-1218.e25.

Science Adv 2022: 8, eabm9427.

Nature 597, 119–125 (2021)

Cell Stem Cell 2020,26(6):845-861.e12.

Science Trans Med 2023,15(701):eadd7872.

STTT 2023,8(1):91.

Cell Reports 2023,42(4):112313

Science Trans Med 2023, 15: eadd7872.

Cancer Cell 2021,39(4):529-547.e7.

Cancer Discov 2022,12(4):1106-1127.

Immunity 2023,56(3):620-634.e11.

J Am Chem Soc 2022,144:21831-21836.

Cell 2020,183:1202-1218.e25.

Science Adv 2022:8,eabm9427.

Nature 2021,597(7874):119-125.

Cell 2020,183:1202-1218.e25.

PNAS Nexus 2022,1(3):pgac063.

ACS Nano 2023,17(10):9110-9125.

Biomaterial 2023 Sep16:302:122333.

Purity & Quality Control Documentation

Current batch：

Purity: ≥98%

COA

MSDS

Instructions

Product Description
Bioactivity & Protocols
Physicochemical Properties
Solubility Data
Calculators
Biological Data

Product Description

Voreloxin HCl (formerly known as AG-7352; SNS-595; SPC 595; AG 7352; SNS595, AG-7352; Vosaroxin), the hydrochloride salt of Voreloxin which is a naphthyridine analog, is a novel and potent Topoisomerase II inhibitor with a broad-spectrum antineoplastic activity. Vosaroxin is an experimental medication that has been given orphan status to treat ovarian cancer and acute myelogenous leukemia (AML). It works by selectively intercalating into DNA to obstruct topoisomerase II's re-ligation process during DNA replication. The result is the inhibition of RNA, protein, and DNA replication, which is followed by cell cycle arrest at the G2 phase and p53-independent apoptosis.

Biological Activity I Assay Protocols (From Reference)

Targets

Topoisomerase II

ln Vitro

Voreloxin Hydrochloride is a novel topoisomerase II poison and inhibitor that causes site-specific DNA DSB, G2 arrest, and apoptosis by intercalating DNA. Voreloxin (0.1–20 µM) causes site-selective DNA DSB in CCRF-CEM cells and inhibits topoisomerase II activity. Voreloxin (0.11, 0.33, 1, 3 µM) partially induces G2 arrest in A549 lung cancer cell line by using topoisomerase II. Voreloxin cytotoxic activity requires DNA intercalation. Nevertheless, Voreloxin (1–9 µM) does not produce a noticeable amount of ROS[1]. In AML cell lines MV4-11 and HL-60, voreloxin exhibits strong cytotoxic activity, with IC50 values of 95 ± 8 nM and 884 ± 114 nM, respectively. In acute leukemia cell lines, voreloxin and cytarabine exhibit additive or synergistic activity[2]. With a mean LD50 of 2.3 μM, voreloxin exhibits activity against primary acute myeloid leukemia (AML). In the myeloid cell lines NB4 and HL-60, voreloxin has an LD50 of 0.59 μM ± 0.25 μM. Voreloxin acts on topoisomerase II and induces cell accumulation in the S and G2 phases of the cell cycle[3].

ln Vivo

Voreloxin (20 mg/kg, i.v.) administered once every four days, twice (q4d ×2), is the only treatment that reduces the cellularity of CD-1 mice's bone marrow by 80%. In mice, voreloxin at 10 mg/kg combined with cytarabine results in marrow ablation, sinusoidal dilatation, and adipocyte infiltration. In bone marrow and peripheral blood CD-1 mice, voreloxin (20 mg/kg, i.v.) and cytarabine induce a reversible decrease in myeloid and lymphoid cells. When voreloxin (10 mg/kg, q4d ×2) and cytarabine are combined, platelets CD-1 mice experience a more mild reversible neutropenia[2].

Cell Assay

MTS cell proliferation assays are used to conduct in vitro toxicity tests on primary AML mononuclear cells over the course of 48 hours. One can calculate lethal doses (LD50). In a final volume of 90 μL, cells are treated with voreloxin (31.25 nM to 4 μM) and Ara-C (62.5 nM to 8 μM) by serial dilution and incubated for 48 hours. After incubation, the reaction is incubated for an additional 4 hours with the addition of 20 μL of MTS reagent. Spectrophotometry is used to measure the absorbance of the reaction at 490 nm after this point, and the percentage of viable cells is computed in relation to the untreated control cells in the same experiment. Software called Calcusyn is used to calculate IC50 values[3].

Animal Protocol

Before beginning therapy, the animals are weighed, randomized according to their body weight, and placed into study groups. On day zero and day four (q4d ×2), voreloxin is given intravenously (IV) at a dose of 10 or 20 mg/kg each time. Day zero and day four (tid q4d ×2) are given cytarabine subcutaneously (SC) at 20 or 60 mg/kg every 8 hours. Three or fewer animals per treatment group, but no more than ten, have their tissues and blood sampled on days six, eight, and twelve. Femurs are immersed for 24 to 48 hours in either the Streck Tissue Fixative solution or the 10% formalin solution, and then they are dehydrated to 70% (ethanol, isopropanol, or methanol). At Biopathology Labs, femurs undergo decalcification, paraffin embedding, and sectioning. Hematoxylin-eosin is used to stain the four micron sections (H&E). Femurs stained with H&E are inspected, and the bone marrow's percentage cellularity is calculated. Using Image-Pro Plus v6.1 software, digital photos of representative femur sections are captured on a Leica DM2000 microscope[2].

References

[1]. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. Expert Opin Pharmacother. 2015 Jun;16(9):1395-402.

[2]. Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo. Cancer Chemother Pharmacol. 2010 Oct;66(5):881-8.

[3]. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica. 2011 Mar;96(3):393-9.

These protocols are for reference only. InvivoChem does not independently validate these methods.

Physicochemical Properties

Molecular Formula

C18H20CLN5O4S

Molecular Weight

437.9

Exact Mass

437.09

CAS #

175519-16-1

Related CAS #

175414-77-4

Appearance

Powder

SMILES

CN[C@H]1CN(C[C@@H]1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O.Cl

InChi Key

JJZCCQHWCOXGCL-QNTKWALQSA-N

InChi Code

InChI=1S/C18H19N5O4S.ClH/c1-19-12-8-22(9-13(12)27-2)14-4-3-10-15(24)11(17(25)26)7-23(16(10)21-14)18-20-5-6-28-18;/h3-7,12-13,19H,8-9H2,1-2H3,(H,25,26);1H/t12-,13-;/m0./s1

Chemical Name

7-[(3S,4S)-3-methoxy-4-(methylamino)pyrrolidin-1-yl]-4-oxo-1-(1,3-thiazol-2-yl)-1,8-naphthyridine-3-carboxylic acid;hydrochloride

Synonyms

Vosaroxin; SNS 595; SPC595; AG7352; SNS595; SPC-595; AG-7352; SNS-595; SPC 595; AG 7352; VVosaroxin

Storage

Powder -20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Solubility Data

Solubility (In Vitro)

DMSO: ~1 mg/mL (~2.3 mM)

Water: ~1 mg/mL (~2.3 mM)

Ethanol: <1 mg/mL

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	2.2836 mL	11.4181 mL	22.8363 mL
	5 mM	0.4567 mL	2.2836 mL	4.5673 mL
	10 mM	0.2284 mL	1.1418 mL	2.2836 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Mass

Concentration

Volume

Molecular Weight*

Calculate Reset

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

Calculate the Mass of a compound required to prepare a solution of known volume and concentration
Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume

See Example

An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?

Enter 350.26 in the Molecular Weight (MW) box
Enter 10 in the Concentration box and choose the correct unit (mM)
Enter 5 in the Volume box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Concentration (Start)

Volume (Start)

Concentration (End)

Volume (End)

Calculate Reset

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:

Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
Enter 25 into the Concentration (End) box and select the correct unit (mM)
Enter 25 into the Volume (End) box and choose the correct unit (mL)
Click the “Calculate” button
The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular formula

Total molecular weight

g/mol

Calculate Reset

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4 c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Calculate Reset

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
Click the “Calculate” button
The answer appears in the Volume (to add to vial) box

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)

Dosage mg/kg

Average weight of animals g

Dosing volume per animal μL

Number of animals

Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

% DMSO

% Tween 80

% ddH₂O

Calculate Reset

Calculation results

Working concentration： mg/mL；

Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O，mix and clarify.

Note： (1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.

Biological Data

Voreloxin combined with cytarabine has additive or synergistic activity in acute leukemia cell lines Viability studies were performed using human acute leukemia cell lines MV4-11, HL-60, and CCRF-CEM exposed for 72 h to serially diluted voreloxin and/or cytarabine. Cancer Chemother Pharmacol . 2010 Oct;66(5):881-8.

Voreloxin and cytarabine, alone or in combination, ablate normal bone marrow CD-1 mice received vehicle, voreloxin, cytarabine, or voreloxin and cytarabine in combination on day 0 and 4. On day 6, femurs were isolated, and cellularity was assessed in H&E stained bone marrow sections. Cancer Chemother Pharmacol . 2010 Oct;66(5):881-8.

The effect of voreloxin on cell cycle distribution was investigated by flow cytometry in (A) NB4 and (B) HL-60 cells following 12 h of treatment. Haematologica . 2011 Mar;96(3):393-9
Synergy between voreloxin and Ara-C was investigated in 25 primary AML samples over 48 h in vitro. Haematologica . 2011 Mar;96(3):393-9.